Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection

Table 4 Distribution of the interferon lambda-4 rs12979860 genotypes based on the clinical features of patients with hepatocellular carcinoma, n = 98

		Genotypes		Codominant model	T allele dominant model
Variable	CC, n = 24	CT, n = 61	TT, n = 13	P value	P value
HCV genotypes				0.052	0.017
1	3 (14.3)	27 (46.6)	8 (61.5)		0.004
2	1(4.8)	2 (3.4)	-
3	17 (81.0)	29 (50.0)	5 (38.5)		0.007
Diabetes	10 (41.7)	19 (31.1)	6 (46.2)	0.463	0.484
Steatosis	1(4.2)	8 (13.3)	2 (16.7)	0.409	0.195
Ascites	10 (41.7)	20 (32.8)	5 (41.7)	0.679	0.511
Portal hypertension	17 (70.8)	48 (78.7)	9 (75.0)	0.741	0.469
Esophageal varices	17 (70.8)	39 (63.9)	9 (75.0)	0.682	0.646
Upper gastrointestinal bleeding	8 (33.3)	10 (16.4)	5 (41.7)	0.075	0.201
Spontaneous bacterial peritonitis	1 (4.2)	5 (8.2)	-	0.500	0.636
Hepatic encephalopathy	3 (12.5)	2 (3.3)	3 (25.0)	0.030	0.383
Child-Pugh				0.209	0.156
A	8 (61.5)	26 (63.4)	8 (88.9)
B	2 (15.4)	12 (29.3)	1 (11.1)
C	3 (23,1)	3 (7.3)	-
Number of tumors				0.325	0.684
1	17 (70.8)	39 (65.0)	6 (46.2)
2	3 (12.5)	12 (20.0)	2 (15.4)
≥ 3	4 (16.7)	9 (15.0)	5 (38.5)
Portal vein thrombosis	4 (16.7)	4 (6.6)	2 (16.7)	0.286	0.238
Extrahepatic metastases	1 (4.2)	5 (8.6)	1 (7.7)	0.780	0.487

Variables expressed as number (percentage). HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus.